ClinicalTrials.gg
CompletedNCT04777747Updated May 1, 2023

The Role of Lactate in Viral and Bacterial Infection

An observational study in Viral Infection, Bacterial Infections and Lactate Blood Increase, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Completed at 1 site in China. Open to participants aged 1 Minute to 18 Years. Per ClinicalTrials.gov, last updated 2023-05-01.

Sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
1 Minute to 18 Years
Sex
All
01

Study summary

Acute upper respiratory tract infection(AURI) is common in children, and viral infection is the main cause. However, several children with viral infection are easy to suffer from secondary bacterial infection, and the mechanism is unclear.

Read the detailed description

Lactate is an important molecule in the spread and metastasis of tumor by suppressing the innate immune response. As is known, the immune system is not mature in children and it is reverse related to the age of children. An reasonable hypothesis is that the lactate is a independent risk factor in the children with viral infection progress to bacterial infection. Here, our aim is to test the hypothesis.

02

Conditions studied

  • Viral Infection
  • Bacterial Infections
  • Lactate Blood Increase
03

In context

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 85 are open to participants now.

This study's enrollment of 400 is close to the median of 442 across 167 observational studies indexed under Virus Diseases.

Browse Virus Diseases studies →

Lead sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University is the lead sponsor of 121 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Minute to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The age of a child ranged from 0 to 18 is included in the present study, especially the first viral infection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • child's age is from 0 to 18 years
  • a child is at least diagnosed with viral infection

Exclusion criteria

Exclusion Criteria:

one of the following conditions appeared:

  • congenital heart disease or other abnormalities
  • respiratory failure
  • hereditary and/or metabolic disease
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (actual)
Patient registry
No

Groups and cohorts

  • viral infection

    a child is infected by virus only

    Other: viral infection

  • viral and bacterial infection

    a child is infected by virus and progress to bacterial infection

    Other: viral and bacterial infection

Interventions

  • Otherviral infection

    a child is infected by virus only

  • Otherviral and bacterial infection

    a child is infected by virus and progress to bacterial infection

06

What researchers measure

Primary outcomes

  1. level of lactate

    level of lactate in both viral and viral and bacterial infection groups

    Time frame: three days after admission

  2. the level of lactate dehydrogenase(LDH)

    level of LDH in both viral and viral and bacterial infection groups

    Time frame: three days after admission

07

Study locations

1 site
  • Chen
    Chongqing, Chongqing 400014, China
08

References and documents

Individual participant data

Plan to share: Yes — two years after the study accomplishment

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: from Jan-1, 2025 to Dec-31, 2025

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04777747
Collaborators
Children's Hospital of Chongqing Medical University
Responsible party
Chen Long,MD (director, Children's Hospital of Chongqing Medical University) — Principal investigator
First posted
Mar 2, 2021
Start date
Jan 1, 2021
Primary completion
Mar 31, 2023
Completion
Mar 31, 2023
Last update
May 1, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion